Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Sell
48
QTTB Quote, Financials, Valuation and Earnings
Last price:
$2.95
Seasonality move
:
-16.61%
Day range:
$2.85 - $3.27
52-week range:
$1.35 - $6.37
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.74x
Volume:
329.1K
Avg. volume:
6.1M
1-year change:
-30.35%
Market cap:
$36.4M
Revenue:
--
EPS (TTM):
-$3.45
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
QTTB
Q32 Bio, Inc.
|
-- | -- | -100% | -- | $15.00 |
|
AKBA
Akebia Therapeutics, Inc.
|
$56.4M | -$0.01 | 20.82% | -95.21% | $5.40 |
|
BLTE
Belite Bio, Inc.
|
-- | -$0.49 | -- | -58.83% | $184.33 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
IVF
INVO Fertility, Inc.
|
$1.8M | -- | -8.8% | -- | -- |
|
KALA
Kala Bio, Inc.
|
-- | -$1.10 | -- | -43.13% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
QTTB
Q32 Bio, Inc.
|
$2.96 | $15.00 | $36.4M | -- | $0.00 | 0% | -- |
|
AKBA
Akebia Therapeutics, Inc.
|
$1.66 | $5.40 | $440.5M | -- | $0.00 | 0% | 1.85x |
|
BLTE
Belite Bio, Inc.
|
$141.32 | $184.33 | $5.3B | -- | $0.00 | 0% | -- |
|
CVM
CEL-SCI Corp.
|
$6.36 | $42.50 | $19.3M | -- | $0.00 | 0% | -- |
|
IVF
INVO Fertility, Inc.
|
$1.34 | -- | $20.3M | -- | $0.00 | 0% | 0.03x |
|
KALA
Kala Bio, Inc.
|
$0.68 | $1.50 | $5.5M | -- | $0.00 | 0% | 7.18x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
QTTB
Q32 Bio, Inc.
|
-1196.42% | 5.520 | 69.88% | 4.41x |
|
AKBA
Akebia Therapeutics, Inc.
|
83.68% | 1.611 | 29.46% | 1.76x |
|
BLTE
Belite Bio, Inc.
|
0.19% | -0.369 | 0.02% | 34.17x |
|
CVM
CEL-SCI Corp.
|
58.65% | 1.679 | 143.38% | 0.32x |
|
IVF
INVO Fertility, Inc.
|
41.99% | -0.446 | 10.12% | 0.07x |
|
KALA
Kala Bio, Inc.
|
140.72% | 1.386 | 263.3% | 0.65x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
QTTB
Q32 Bio, Inc.
|
-$91K | -$7.6M | -256.32% | -634.27% | -- | -$4.2M |
|
AKBA
Akebia Therapeutics, Inc.
|
$49.1M | $4.4M | -7.86% | -- | 7.57% | $28M |
|
BLTE
Belite Bio, Inc.
|
-$347K | -$23M | -37.09% | -37.13% | -- | -- |
|
CVM
CEL-SCI Corp.
|
-$959K | -$5.5M | -123.39% | -266.61% | -- | -$3.9M |
|
IVF
INVO Fertility, Inc.
|
$492.6K | -$1.6M | -188.23% | -471.28% | -93.08% | -$1.8M |
|
KALA
Kala Bio, Inc.
|
-$128K | -$10.7M | -102.67% | -1375.54% | -- | -$10.9M |
Q32 Bio, Inc. vs. Competitors
-
Which has Higher Returns QTTB or AKBA?
Akebia Therapeutics, Inc. has a net margin of -- compared to Q32 Bio, Inc.'s net margin of 0.92%. Q32 Bio, Inc.'s return on equity of -634.27% beat Akebia Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital QTTBQ32 Bio, Inc.-- -$0.60 -$1.4M AKBAAkebia Therapeutics, Inc.83.49% $0.00 $254.9M -
What do Analysts Say About QTTB or AKBA?
Q32 Bio, Inc. has a consensus price target of $15.00, signalling upside risk potential of 406.76%. On the other hand Akebia Therapeutics, Inc. has an analysts' consensus of $5.40 which suggests that it could grow by 225.3%. Given that Q32 Bio, Inc. has higher upside potential than Akebia Therapeutics, Inc., analysts believe Q32 Bio, Inc. is more attractive than Akebia Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings QTTBQ32 Bio, Inc.1 1 0 AKBAAkebia Therapeutics, Inc.4 0 0 -
Is QTTB or AKBA More Risky?
Q32 Bio, Inc. has a beta of 0.227, which suggesting that the stock is 77.253% less volatile than S&P 500. In comparison Akebia Therapeutics, Inc. has a beta of 0.311, suggesting its less volatile than the S&P 500 by 68.934%.
-
Which is a Better Dividend Stock QTTB or AKBA?
Q32 Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akebia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Q32 Bio, Inc. pays -- of its earnings as a dividend. Akebia Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QTTB or AKBA?
Q32 Bio, Inc. quarterly revenues are --, which are smaller than Akebia Therapeutics, Inc. quarterly revenues of $58.8M. Q32 Bio, Inc.'s net income of -$7.4M is lower than Akebia Therapeutics, Inc.'s net income of $540K. Notably, Q32 Bio, Inc.'s price-to-earnings ratio is -- while Akebia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Q32 Bio, Inc. is -- versus 1.85x for Akebia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QTTBQ32 Bio, Inc.-- -- -- -$7.4M AKBAAkebia Therapeutics, Inc.1.85x -- $58.8M $540K
-
Which has Higher Returns QTTB or BLTE?
Belite Bio, Inc. has a net margin of -- compared to Q32 Bio, Inc.'s net margin of --. Q32 Bio, Inc.'s return on equity of -634.27% beat Belite Bio, Inc.'s return on equity of -37.13%.
Company Gross Margin Earnings Per Share Invested Capital QTTBQ32 Bio, Inc.-- -$0.60 -$1.4M BLTEBelite Bio, Inc.-- -$0.65 $274.6M -
What do Analysts Say About QTTB or BLTE?
Q32 Bio, Inc. has a consensus price target of $15.00, signalling upside risk potential of 406.76%. On the other hand Belite Bio, Inc. has an analysts' consensus of $184.33 which suggests that it could grow by 30.44%. Given that Q32 Bio, Inc. has higher upside potential than Belite Bio, Inc., analysts believe Q32 Bio, Inc. is more attractive than Belite Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings QTTBQ32 Bio, Inc.1 1 0 BLTEBelite Bio, Inc.5 0 0 -
Is QTTB or BLTE More Risky?
Q32 Bio, Inc. has a beta of 0.227, which suggesting that the stock is 77.253% less volatile than S&P 500. In comparison Belite Bio, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QTTB or BLTE?
Q32 Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Belite Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Q32 Bio, Inc. pays -- of its earnings as a dividend. Belite Bio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QTTB or BLTE?
Q32 Bio, Inc. quarterly revenues are --, which are smaller than Belite Bio, Inc. quarterly revenues of --. Q32 Bio, Inc.'s net income of -$7.4M is higher than Belite Bio, Inc.'s net income of -$21.7M. Notably, Q32 Bio, Inc.'s price-to-earnings ratio is -- while Belite Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Q32 Bio, Inc. is -- versus -- for Belite Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QTTBQ32 Bio, Inc.-- -- -- -$7.4M BLTEBelite Bio, Inc.-- -- -- -$21.7M
-
Which has Higher Returns QTTB or CVM?
CEL-SCI Corp. has a net margin of -- compared to Q32 Bio, Inc.'s net margin of --. Q32 Bio, Inc.'s return on equity of -634.27% beat CEL-SCI Corp.'s return on equity of -266.61%.
Company Gross Margin Earnings Per Share Invested Capital QTTBQ32 Bio, Inc.-- -$0.60 -$1.4M CVMCEL-SCI Corp.-- -$1.36 $17M -
What do Analysts Say About QTTB or CVM?
Q32 Bio, Inc. has a consensus price target of $15.00, signalling upside risk potential of 406.76%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 568.24%. Given that CEL-SCI Corp. has higher upside potential than Q32 Bio, Inc., analysts believe CEL-SCI Corp. is more attractive than Q32 Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings QTTBQ32 Bio, Inc.1 1 0 CVMCEL-SCI Corp.1 0 0 -
Is QTTB or CVM More Risky?
Q32 Bio, Inc. has a beta of 0.227, which suggesting that the stock is 77.253% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock QTTB or CVM?
Q32 Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Q32 Bio, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QTTB or CVM?
Q32 Bio, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Q32 Bio, Inc.'s net income of -$7.4M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Q32 Bio, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Q32 Bio, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QTTBQ32 Bio, Inc.-- -- -- -$7.4M CVMCEL-SCI Corp.-- -- -- -$5.7M
-
Which has Higher Returns QTTB or IVF?
INVO Fertility, Inc. has a net margin of -- compared to Q32 Bio, Inc.'s net margin of -150.51%. Q32 Bio, Inc.'s return on equity of -634.27% beat INVO Fertility, Inc.'s return on equity of -471.28%.
Company Gross Margin Earnings Per Share Invested Capital QTTBQ32 Bio, Inc.-- -$0.60 -$1.4M IVFINVO Fertility, Inc.28.04% -$6.14 $10.1M -
What do Analysts Say About QTTB or IVF?
Q32 Bio, Inc. has a consensus price target of $15.00, signalling upside risk potential of 406.76%. On the other hand INVO Fertility, Inc. has an analysts' consensus of -- which suggests that it could grow by 10646.27%. Given that INVO Fertility, Inc. has higher upside potential than Q32 Bio, Inc., analysts believe INVO Fertility, Inc. is more attractive than Q32 Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings QTTBQ32 Bio, Inc.1 1 0 IVFINVO Fertility, Inc.0 0 0 -
Is QTTB or IVF More Risky?
Q32 Bio, Inc. has a beta of 0.227, which suggesting that the stock is 77.253% less volatile than S&P 500. In comparison INVO Fertility, Inc. has a beta of 2.540, suggesting its more volatile than the S&P 500 by 153.97%.
-
Which is a Better Dividend Stock QTTB or IVF?
Q32 Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. INVO Fertility, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Q32 Bio, Inc. pays -- of its earnings as a dividend. INVO Fertility, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QTTB or IVF?
Q32 Bio, Inc. quarterly revenues are --, which are smaller than INVO Fertility, Inc. quarterly revenues of $1.8M. Q32 Bio, Inc.'s net income of -$7.4M is lower than INVO Fertility, Inc.'s net income of -$2.6M. Notably, Q32 Bio, Inc.'s price-to-earnings ratio is -- while INVO Fertility, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Q32 Bio, Inc. is -- versus 0.03x for INVO Fertility, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QTTBQ32 Bio, Inc.-- -- -- -$7.4M IVFINVO Fertility, Inc.0.03x -- $1.8M -$2.6M
-
Which has Higher Returns QTTB or KALA?
Kala Bio, Inc. has a net margin of -- compared to Q32 Bio, Inc.'s net margin of --. Q32 Bio, Inc.'s return on equity of -634.27% beat Kala Bio, Inc.'s return on equity of -1375.54%.
Company Gross Margin Earnings Per Share Invested Capital QTTBQ32 Bio, Inc.-- -$0.60 -$1.4M KALAKala Bio, Inc.-- -$1.07 $21.3M -
What do Analysts Say About QTTB or KALA?
Q32 Bio, Inc. has a consensus price target of $15.00, signalling upside risk potential of 406.76%. On the other hand Kala Bio, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 122.16%. Given that Q32 Bio, Inc. has higher upside potential than Kala Bio, Inc., analysts believe Q32 Bio, Inc. is more attractive than Kala Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings QTTBQ32 Bio, Inc.1 1 0 KALAKala Bio, Inc.0 2 0 -
Is QTTB or KALA More Risky?
Q32 Bio, Inc. has a beta of 0.227, which suggesting that the stock is 77.253% less volatile than S&P 500. In comparison Kala Bio, Inc. has a beta of -2.494, suggesting its less volatile than the S&P 500 by 349.43%.
-
Which is a Better Dividend Stock QTTB or KALA?
Q32 Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kala Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Q32 Bio, Inc. pays -- of its earnings as a dividend. Kala Bio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QTTB or KALA?
Q32 Bio, Inc. quarterly revenues are --, which are smaller than Kala Bio, Inc. quarterly revenues of --. Q32 Bio, Inc.'s net income of -$7.4M is higher than Kala Bio, Inc.'s net income of -$7.6M. Notably, Q32 Bio, Inc.'s price-to-earnings ratio is -- while Kala Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Q32 Bio, Inc. is -- versus 7.18x for Kala Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QTTBQ32 Bio, Inc.-- -- -- -$7.4M KALAKala Bio, Inc.7.18x -- -- -$7.6M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
73
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 39x
Alerts
Buy
80
FEIM alert for Dec 13
Frequency Electronics, Inc. [FEIM] is up 28.76% over the past day.
Buy
57
MOD alert for Dec 13
Modine Manufacturing Co. [MOD] is down 15.32% over the past day.
Sell
42
OKLO alert for Dec 13
Oklo, Inc. [OKLO] is down 14.91% over the past day.
